Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.
Africa
/ epidemiology
Angola
Cost of Illness
Delivery of Health Care
/ standards
Diphtheria-Tetanus-Pertussis Vaccine
/ administration & dosage
Ethiopia
Guinea
Humans
Immunization
/ economics
Infant
Models, Theoretical
Morocco
Rwanda
Socioeconomic Factors
Somalia
Spatio-Temporal Analysis
Vaccination
/ statistics & numerical data
Vaccination Coverage
/ statistics & numerical data
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
04 May 2019
04 May 2019
Historique:
received:
05
05
2018
revised:
19
12
2018
accepted:
15
01
2019
pubmed:
10
4
2019
medline:
23
5
2019
entrez:
10
4
2019
Statut:
ppublish
Résumé
Routine childhood vaccination is among the most cost-effective, successful public health interventions available. Amid substantial investments to expand vaccine delivery throughout Africa and strengthen administrative reporting systems, most countries still require robust measures of local routine vaccine coverage and changes in geographical inequalities over time. This analysis drew from 183 surveys done between 2000 and 2016, including data from 881 268 children in 49 African countries. We used a Bayesian geostatistical model calibrated to results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, to produce annual estimates with high-spatial resolution (5 × 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 months in 52 African countries from 2000 to 2016. Estimated third-dose (DPT3) coverage increased in 72·3% (95% uncertainty interval [UI] 64·6-80·3) of second-level administrative units in Africa from 2000 to 2016, but substantial geographical inequalities in DPT coverage remained across and within African countries. In 2016, DPT3 coverage at the second administrative (ie, district) level varied by more than 25% in 29 of 52 countries, with only two (Morocco and Rwanda) of 52 countries meeting the Global Vaccine Action Plan target of 80% DPT3 coverage or higher in all second-level administrative units with high confidence (posterior probability ≥95%). Large areas of low DPT3 coverage (≤50%) were identified in the Sahel, Somalia, eastern Ethiopia, and in Angola. Low first-dose (DPT1) coverage (≤50%) and high relative dropout (≥30%) together drove low DPT3 coverage across the Sahel, Somalia, eastern Ethiopia, Guinea, and Angola. Despite substantial progress in Africa, marked national and subnational inequalities in DPT coverage persist throughout the continent. These results can help identify areas of low coverage and vaccine delivery system vulnerabilities and can ultimately support more precise targeting of resources to improve vaccine coverage and health outcomes for African children. Bill & Melinda Gates Foundation.
Sections du résumé
BACKGROUND
BACKGROUND
Routine childhood vaccination is among the most cost-effective, successful public health interventions available. Amid substantial investments to expand vaccine delivery throughout Africa and strengthen administrative reporting systems, most countries still require robust measures of local routine vaccine coverage and changes in geographical inequalities over time.
METHODS
METHODS
This analysis drew from 183 surveys done between 2000 and 2016, including data from 881 268 children in 49 African countries. We used a Bayesian geostatistical model calibrated to results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, to produce annual estimates with high-spatial resolution (5 × 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 months in 52 African countries from 2000 to 2016.
FINDINGS
RESULTS
Estimated third-dose (DPT3) coverage increased in 72·3% (95% uncertainty interval [UI] 64·6-80·3) of second-level administrative units in Africa from 2000 to 2016, but substantial geographical inequalities in DPT coverage remained across and within African countries. In 2016, DPT3 coverage at the second administrative (ie, district) level varied by more than 25% in 29 of 52 countries, with only two (Morocco and Rwanda) of 52 countries meeting the Global Vaccine Action Plan target of 80% DPT3 coverage or higher in all second-level administrative units with high confidence (posterior probability ≥95%). Large areas of low DPT3 coverage (≤50%) were identified in the Sahel, Somalia, eastern Ethiopia, and in Angola. Low first-dose (DPT1) coverage (≤50%) and high relative dropout (≥30%) together drove low DPT3 coverage across the Sahel, Somalia, eastern Ethiopia, Guinea, and Angola.
INTERPRETATION
CONCLUSIONS
Despite substantial progress in Africa, marked national and subnational inequalities in DPT coverage persist throughout the continent. These results can help identify areas of low coverage and vaccine delivery system vulnerabilities and can ultimately support more precise targeting of resources to improve vaccine coverage and health outcomes for African children.
FUNDING
BACKGROUND
Bill & Melinda Gates Foundation.
Identifiants
pubmed: 30961907
pii: S0140-6736(19)30226-0
doi: 10.1016/S0140-6736(19)30226-0
pmc: PMC6497987
pii:
doi:
Substances chimiques
Diphtheria-Tetanus-Pertussis Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1843-1855Subventions
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : T32 HD007242
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Bull World Health Organ. 2008 Mar;86(3):A-B
pubmed: 18368190
Bull World Health Organ. 2009 Jul;87(7):535-41
pubmed: 19649368
Vaccine. 2011 Oct 26;29(46):8215-21
pubmed: 21893149
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Health Aff (Millwood). 2016 Feb;35(2):242-9
pubmed: 26858376
Health Aff (Millwood). 2016 Feb;35(2):250-8
pubmed: 26858377
Lancet Glob Health. 2016 Oct;4(10):e726-35
pubmed: 27569362
N Engl J Med. 2016 Dec 22;375(25):2435-2445
pubmed: 27723434
Sci Data. 2017 Jan 31;4:170004
pubmed: 28140397
Bull World Health Organ. 2017 Sep 1;95(9):629-638
pubmed: 28867843
Lancet. 2017 Sep 16;390(10100):1423-1459
pubmed: 28916366
Lancet. 2017 Sep 16;390(10100):1084-1150
pubmed: 28919115
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
J R Soc Interface. 2017 Sep;14(134):
pubmed: 28931634
Lancet. 2017 Nov 11;390(10108):2171-2182
pubmed: 28958464
Nature. 2017 Nov 16;551(7680):273
pubmed: 29144479
Vaccine. 2018 Mar 14;36(12):1583-1591
pubmed: 29454519
Nature. 2018 Feb 28;555(7694):48-53
pubmed: 29493588
Nature. 2018 Feb 28;555(7694):41-47
pubmed: 29493591